The Antitumoral Effect of the Long-Acting Somatostatin Analog Lanreotide in Neuroendocrine Tumors

Ducreux, Michel; Ruszniewski, Philippe; Chayvialle, Jean-Alain; Blumberg, Joëlle; Cloarec, Denis; Michel, Henri; Raymond, Jean Michel; Dupas, Jean-Louis; Gouerou, Hervé; Jian, Raymond; Genestin, Elisabeth; Hammel, Pascal; Rougier, Philippe
November 2000
American Journal of Gastroenterology;Nov2000, Vol. 95 Issue 11, p3276
Academic Journal
OBJECTIVE: Somatostatin analogs are the first-line drugs for controlling hormone-mediated symptoms of carcinoid tumors. Prospective and retrospective studies have suggested that somatostatin analogs also have antiproliferative activity. The octapeptide lanreotide is available in sustained-release form, obviating the need for daily injections. METHODS: A total of 46 patients were enrolled in this open, prospective, phase II trial. They received lanreotide 30 mg i.m. every 14 days for 6 months when they had symptomatic carcinoid tumors, and lanreotide 30 mg i.m. every 10 days if they had nonsymptomatic tumors. Nonsymptomatic tumors were progressive before the start of the study. Tumor size was assessed every 3 months by means of computed tomography. The assessment was centralized and was made by an external panel. RESULTS: In all. 30 patients had symptomatic neuroendocrine tumors and 16 had asymptomatic neuroendocrine tumors. Five patients in the group with symptomatic tumors and two in the group with nonsymptomatic tumors were considered not to be evaluable. The mean duration of treatment was 12 months in the group with symptomatic tumors and 13 months in the other group. Among the 39 evaluable patients, two objective responses were obtained, giving an objective response rate of 5% (one in the group with symptomatic tumors and one in the other group). Nineteen patients had no significant increase in their tumor size for a mean of 9.5 months. CONCLUSIONS: Lanreotide is safe and well tolerated in patients with carcinoid tumors. It seems to have both symptomatic and antitumoral effects in this setting.


Related Articles

  • [sup 99m]Tc-Demotate 1: first data in tumour patients—results of a pilot/phase I study. Decristoforo, Clemens; Mama, Theodosia; Nock, Berthold; Gabriel, Michael; Cordopatis, Paul; Moncayo, Roy // European Journal of Nuclear Medicine & Molecular Imaging;2003, Vol. 30 Issue 9, p1211 

    Abstract Somatostatin receptor (SSTR) scintigraphy with indium-111 DTPA-octreotide has become a routine diagnostic procedure in oncology. However, it suffers some drawbacks concerning the limited availability, sub-optimal imaging properties and elevated radiation burden of "In. We have recently...

  • Prophylactic Cholecystectomy in Midgut Carcinoid Patients. Norlén, Olov; Hessman, Ola; Stålberg, Peter; Åkerström, Göran; Hellman, Per // World Journal of Surgery;Jun2010, Vol. 34 Issue 6, p1361 

    Patients with midgut carcinoid (MGC) tumors are commonly treated with somatostatin analogs. Adverse effects of these drugs include impairment of gallbladder function, formation of gallstones, and cholecystitis. Prophylactic cholecystectomy has been advocated, but data to support this...

  • Carcinoid tumors: Challenges and considerations during anesthetic management. Singh Bajwa, Sukhminder Jit; Panda, Aparajita; Kaur, Gurpreet // Journal of the Scientific Society;Sep/Oct2015, Vol. 42 Issue 3, p132 

    Carcinoid tumors are rare, slow-growing neoplasms of neuroendocrine tissues from enterochromaffin or kulchitsky cells, which have the potential to metastasize. The mediators released from these tumors when bypass the hepatic metabolism, can lead to the possible development of carcinoid syndrome....

  • Changing Treatment Strategy for Gastrinoma in Patients with Zollinger-Ellison Syndrome. Imamura, Masayuki; Komoto, Izumi; Ota, Shuichi // World Journal of Surgery;Jan2006, Vol. 30 Issue 1, p1 

    We overviewed the recent development of curative surgery for gastrinoma that has been rapidly improved since the development of new localization techniques, especially the selective arterial secretagogue injection test (SASI test) and somatostatin receptor scintigraphy (SRS). A number of new...

  • Remission of symptoms during long term treatment of metastatic pancreatic endocrine tumors with long acting somatostatin analogue. Ch'ng, J.L.C.; Anderson, J.V.; Williams, S.J.; Carr, D.H.; Bloom, S.R. // British Medical Journal (Clinical Research Edition);4/12/1986, Vol. 292 Issue 6526, p981 

    Examines the remission of symptoms during the long term treatment of metastatic pancreatic endocrine tumors or apudomas with somatostatin analogue. Reduction in tumor related hormone concentrations; Tolerance for the treatment; Methods of treatment.

  • Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung. García-Yuste, Mariano; Matilla, José M.; Cueto, Antonio; Paniagua, José Manuel Rodríguez; Ramos, Guillermo; Cañizares, Miguel Angel; Muguruza, Ignacio // European Journal of Cardio-Thoracic Surgery;Feb2007, Vol. 31 Issue 2, p192 

    Abstract: Background: This study examines the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung with patients treated surgically for typical and atypical carcinoid tumours. Methods: From 1980 to 2002, 661 patients were treated surgically for 569 typical...

  • Ulcerative colitis: value of MR imaging. Maccioni, F.; Colaiacomo, M. C.; Parlanti, S. // Abdominal Imaging;Sep/Oct2005, Vol. 30 Issue 5, p584 

    Recent technologic advances have greatly improved the quality of abdominal magnetic resonance imaging (MRI) by allowing the identification of abnormalities in inflammatory bowel disease. Thus far, the role of MRI has been extensively investigated in Crohn disease (CD) and, to a minor extent, in...

  • Effects of Somatostatin Infusion in Four Patients with Malignant Carcinoid Syndrome. Quatrini, Maurizio; Basilisco, Guido; Conte, Dario; Bozzani, Angelo; Bardella, Maria Teresa; Bianchi, Paolo A. // American Journal of Gastroenterology;Mar1983, Vol. 78 Issue 3, p149 

    Somatostatin (4 µg/min, cyclic form) was infused for 24 h on six occasions in four patients with carcinoid ileal tumor and multiple liver metastases. During infusion, spontaneous flushes and/or diarrhea were markedly reduced with a return to the pretreatment pattern on the next day. Urinary...

  • The Radiology Corner. Marshak, Richard H.; Lindner, Arthur E. // American Journal of Gastroenterology;Aug1972, Vol. 58 Issue 2, p185 

    Presents a medical case of a carcinoid tumor of the colon. Case report of the patient; Radiologic diagnostic procedures conducted; Description of the tumor.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics